



NATH SEEDS®

**Nath Bio-Genes (I) Ltd.**

(CIN L01110MH1993PLC072842)

18<sup>th</sup> January 2024

The Manager-Listing  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001

The Manager- Listing  
National Stock Exchange of India Ltd.,  
Exchange Plaza, Bandra-Kurla Complex  
Bandra (E)  
Mum bai-400051

BSE Code-537291

NSE Code-NATHBIOGEN

Sub - Outcome of Board Meeting.

Ref – Regulation 30 and Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements).

We inform you that the Board of Directors of the Company, at its Meeting held today i.e. on Thursday, 18<sup>th</sup> January 2024, has approved the standalone and Consolidated unaudited financial results, for the quarter and nine months ended 31<sup>st</sup> December, 2023.

Pursuant to above-referred regulations, we enclose the following documents.

1. Statement of unaudited Standalone financial results, for the quarter and nine months ended 31<sup>st</sup> December, 2023 (Annexure-I)
2. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-II)
3. Statement of unaudited Consolidated financial results, for the quarter and nine months ended 31<sup>st</sup> December, 2023 (Annexure-III)
4. Limited Review Report of the Statutory Auditors on the aforesaid Financial Results. (Annexure-IV).
5. The Board of Directors of the Company has considered and given approval for giving loan or guarantee or providing security in connected with loan availed by the Company's Subsidiary, or Associate or Joint Venture or Group Entity of the Company, or any other person in which any of the Director of the Company is deemed to be interested as specified under section 185 of the Companies Act, 2013. (collectively referred to as the "Entities"), up to a sum not exceeding Rs. 250 Crores [Rupees Two Hundred and Fifty Crores Only] at any point in time, in its absolute discretion deem beneficial and in the best interest of the Company., subject to Approval of Shareholders of the Company.
6. Approved and Fix the date of Extra Ordinary General Meeting of the Company to be held on Tuesday 12<sup>th</sup> March 2024 at 11.00 am through video conference/other audio visual means accordance with the applicable circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India.

The procedure for participation in the Extra Ordinary General Meeting will be intimated separately.

7. Approved the closure of the Register of Members of the Company from 08<sup>th</sup> March 2024 to 12<sup>th</sup> March 2024 (both days inclusive for the purpose of EOGM).



NATH SEEDS®

**Nath Bio-Genes (I) Ltd.**

(CIN L01110MH1993PLC072842)

Kindly note that detail Notice and Resolution for the Extra Ordinary General Meeting along with the Explanatory Statement will be intimated separately.

The Meeting Commenced on 04:30 p.m. and concluded on 06:15 p.m.

The above information will be made available on the Company's website  
[www.nathbiogenes.com](http://www.nathbiogenes.com).

You are requested to take the above information on record.

Thanking You.

Yours faithfully,  
For Nath Bio-Genes (India) Limited,

Devinder Khurana  
Chief Financial Officer

NATH SEEDS

हर बीज खरा, शक्ति भरा

■ Nath House, Nath Road, Aurangabad - 431005 (MS) Tel : 0240-2376314/5/6/7  
Email : [info@nathseeds.com](mailto:info@nathseeds.com) [www.nathbiogenes.com](http://www.nathbiogenes.com)

■ 1, Chateau Windsor, 86 Veer Nariman Road, Mumbai - 400020 (MS) Tel : 022-22871001, 22875653/4/5

**NATH**  
GROUP

**Nath Bio-Genes (I) Ltd.**

(CIN L01110MH1993PLC072642)

**STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31/12/2023**

S. No.	Particulars	Quarter Ended			Nine Months Ended		Rs in Lacs
		31-12-2023	30-09-2023	31-12-2022	31-12-2023	31-12-2022	Year Ended
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	31-03-2023 Audited
I	<b>Income from operations</b>						
	(a) Revenue from operations	3,173.76	2,256.77	2,529.74	28,958.69	25,637.62	30,129.15
	(b) Other Operating Income	-	-	-	-	-	-
	<b>Total Income</b>	<b>3,173.76</b>	<b>2,256.77</b>	<b>2,529.74</b>	<b>28,958.69</b>	<b>25,637.62</b>	<b>30,129.15</b>
II	<b>Expenses</b>						
	a) Production & Seed Conditioning Expenses	834.53	566.32	1,214.40	8,343.34	8,143.63	11,730.07
	b) Purchase of Stock-in-Trade	240.92	408.44	185.77	846.12	621.49	530.84
	c) Change in Inventories of Produced and Traded Goods	336.78	-551.01	-441.37	4,922.02	3,029.48	1,198.25
	d) Employee Benefit Expense	592.80	785.80	467.50	2,090.59	1,719.57	2,322.95
	e) Depreciation & Amortisation Expenses	76.00	76.00	67.40	228.00	202.19	301.23
	f) Selling & Distribution Expenses	198.54	158.12	181.52	6,642.13	6,306.74	7,077.77
	g) Other Expenses	391.86	380.73	360.40	1,324.19	1,335.72	2,380.20
	<b>Total Expenses</b>	<b>2,671.43</b>	<b>1,824.42</b>	<b>2,035.62</b>	<b>24,396.39</b>	<b>21,358.82</b>	<b>25,541.31</b>
III	<b>Profit from Operations before other income, finance cost and Exceptional Items (I-II)</b>	<b>502.33</b>	<b>432.35</b>	<b>494.12</b>	<b>4,562.30</b>	<b>4,278.80</b>	<b>4,587.84</b>
IV	<b>Other Income</b>	<b>3.74</b>	<b>6.15</b>	<b>5.81</b>	<b>21.59</b>	<b>29.72</b>	<b>56.04</b>
V	<b>Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)</b>	<b>506.07</b>	<b>438.50</b>	<b>499.93</b>	<b>4,583.89</b>	<b>4,308.52</b>	<b>4,643.88</b>
VI	<b>Finance Cost</b>	<b>283.75</b>	<b>243.65</b>	<b>295.52</b>	<b>803.85</b>	<b>858.86</b>	<b>1,012.08</b>
VII	<b>Profit from Ordinary Activities after Finance cost (V-VI)</b>	<b>222.32</b>	<b>194.85</b>	<b>204.42</b>	<b>3,780.04</b>	<b>3,449.65</b>	<b>3,631.80</b>
VIII	<b>Exceptional Items Income/(Expenses)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
IX	<b>Profit from Ordinary Activities before Tax (VII-VIII)</b>	<b>222.32</b>	<b>194.85</b>	<b>204.42</b>	<b>3,780.04</b>	<b>3,449.65</b>	<b>3,631.80</b>
X	<b>Tax Expense</b>						
	(a) Current Tax	76.57	33.03	69.54	131.61	92.20	118.64
	(b) Earlier Year Tax	-	1.50	-	1.50	-	-3.35
	(c) Deferred Tax	-	-	-	-	-	-
XI	<b>Net Profit from Ordinary Activities after Tax (IX-X)</b>	<b>145.75</b>	<b>160.32</b>	<b>134.88</b>	<b>3,646.93</b>	<b>3,357.45</b>	<b>3,516.51</b>
XII	<b>Extra Ordinary Items (Net of Tax)</b>	<b>-249.98</b>	<b>-</b>	<b>-</b>	<b>-249.98</b>	<b>-</b>	<b>-</b>
XIII	<b>Net Profit for the period (XI-XII)</b>	<b>395.73</b>	<b>160.32</b>	<b>134.88</b>	<b>3,896.91</b>	<b>3,357.45</b>	<b>3,516.51</b>
XIV	<b>Other Comprehensive Income</b>						
	1. (a) Items that will not be reclassified to Profit or Loss	-0.56	-0.54	-	-1.50	-	-2.06
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	2. (a) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	(b) Income tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>-0.56</b>	<b>-0.54</b>	<b>-</b>	<b>-1.50</b>	<b>-</b>	<b>-2.06</b>
XV	<b>Total Comprehensive Income for the period (XIII + XIV)</b>	<b>396.29</b>	<b>160.86</b>	<b>134.88</b>	<b>3,898.41</b>	<b>3,357.45</b>	<b>3,518.57</b>
XVI	<b>Paid Up Equity Share Capital (Face Value Rs. 10/- each)</b>	<b>1,900.40</b>	<b>1,900.40</b>	<b>1,900.40</b>	<b>1,900.40</b>	<b>1,900.40</b>	<b>1,900.40</b>
XVII	<b>Reserve &amp; Surplus</b>	<b>58,953.36</b>	<b>58,556.13</b>	<b>55,653.99</b>	<b>58,953.36</b>	<b>55,653.99</b>	<b>55,435.02</b>
XVIII	<b>Earning per share (of Rs 10/- each) (not annualised) Basic &amp; Diluted</b>	<b>2.09</b>	<b>0.85</b>	<b>0.71</b>	<b>20.51</b>	<b>17.67</b>	<b>18.51</b>

**NOTES:**

(1) The Standalone Financial Results were reviewed by the Audit Committee in meeting held on 15 January 2024 and were thereafter approved by the Board of Directors at its meeting held on 18 January 2024

(2) The company is dealing in one major product segment, i.e. Seed Cultivation.

(3) Investor complaints - Opening Balance - 0, Received and Resolved - 0, Closing Balance - 0

(4) The figures have been regrouped/rearranged where ever necessary.

FOR NATH BIO-GENES (INDIA) LTD.

SATISH KAGLIWAL  
MANAGING DIRECTOR  
DIN 00119601



Place : Aurangabad

Date : 18 January 2023

Regd. Office : Nath House, Nath Road, Aurangabad - 431005 (MS)  
www.nathbiogenes.com



# Gautam N Associates

## Chartered Accountants

30, GNA House, Behind ABC Complex,  
Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

### INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDLONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.

To  
The Board of Directors,  
Nath Bio-Genes India Limited  
Aurangabad

1. We have reviewed the accompanying statement of unaudited Standalone financial results of **Nath Bio-Genes India Limited** for the quarter ended 31<sup>st</sup> December 2023 and year to date results for the period 1<sup>st</sup> April 2023 to 31<sup>st</sup> December 2023 ('The Statement') being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as modified.
2. This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued there under and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.


For Gautam N Associates  
Chartered Accountants  
FRN: 103117W

*Gautam*



Gautam Nandawat  
Partner  
M No. 032742  
UDIN: 24032742BKCRNN8255

Place: Chhatrapati Sambhajnagar  
Date: 18<sup>th</sup> January 2024



# Nath Bio-Genes (I) Ltd.

(CIN L01110MH1993PLC072842)

## STATEMENT OF CONSOLIDATED UNAUDITED RESULTS FOR THE QUARTER AND 9 MONTHS ENDED 31/12/2023

Rs in Lakhs

S. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31-12-2023 Unaudited	30-09-2023 Unaudited	31-12-2022 Unaudited	31-12-2023 Unaudited	31-12-2022 Unaudited	31-03-2023 Audited
I	<b>Income from operations</b>						
	(a) Revenue from operations	3,173.76	2,256.77	2,529.74	28,958.69	25,637.62	30,136.37
	(b) Other Operating Income	-	-	-	-	-	-
	<b>Total Income</b>	<b>3,173.76</b>	<b>2,256.77</b>	<b>2,529.74</b>	<b>28,958.69</b>	<b>25,637.62</b>	<b>30,136.37</b>
II	<b>Expenses</b>						
	a) Production & Seed Conditioning Expenses	836.28	566.32	1,214.40	8,345.09	8,143.63	11,732.15
	b) Purchase of Stock-in-Trade	242.39	408.44	185.77	854.58	621.49	530.84
	c) Change in Inventories of Produced and Traded Goods	335.31	-551.01	-441.37	4,913.56	3,029.48	1,198.25
	d) Employee Benefit Expense	598.66	785.80	467.50	2,107.85	1,719.57	2,331.51
	e) Depreciation & Amortisation Expenses	76.00	76.00	67.40	228.00	202.19	301.23
	f) Selling & Distribution Expenses	198.54	158.12	181.52	6,642.13	6,306.74	7,083.26
	g) Other Expenses	398.03	380.73	360.40	1,352.11	1,335.72	2,385.97
	<b>Total Expenses</b>	<b>2,685.21</b>	<b>1,824.42</b>	<b>2,035.62</b>	<b>24,443.32</b>	<b>21,358.82</b>	<b>25,563.21</b>
III	<b>Profit from Operations before other income, finance cost and Exceptional Items (I-II)</b>	<b>488.55</b>	<b>432.35</b>	<b>494.12</b>	<b>4,515.37</b>	<b>4,278.80</b>	<b>4,573.16</b>
IV	<b>Other Income</b>	3.74	6.15	5.81	21.59	29.72	55.35
V	<b>Profit from Ordinary Activities before Finance cost and Exceptional Items (III+IV)</b>	<b>492.29</b>	<b>438.50</b>	<b>499.93</b>	<b>4,536.96</b>	<b>4,308.52</b>	<b>4,628.51</b>
VI	<b>Finance Cost</b>	283.75	243.65	295.52	803.85	858.86	1,012.08
VII	<b>Profit from Ordinary Activities after Finance cost (V-VI)</b>	<b>208.54</b>	<b>194.85</b>	<b>204.42</b>	<b>3,733.11</b>	<b>3,449.65</b>	<b>3,616.43</b>
VIII	<b>Exceptional Items Income/(Expenses)</b>	-	-	-	-	-	-
IX	<b>Profit from Ordinary Activities before Tax (VII-VIII)</b>	<b>208.54</b>	<b>194.85</b>	<b>204.42</b>	<b>3,733.11</b>	<b>3,449.65</b>	<b>3,616.43</b>
X	<b>Tax Expense</b>						
	(a) Current Tax	76.67	33.03	69.54	131.61	92.20	118.64
	(b) Earlier Year Tax	-	1.50	-	1.50	-	-3.35
	(c) Deferred Tax	-	-	-	-	-	-
XI	<b>Net Profit from Ordinary Activities after Tax (IX-X)</b>	<b>131.97</b>	<b>160.32</b>	<b>134.88</b>	<b>3,600.00</b>	<b>3,357.45</b>	<b>3,501.14</b>
XII	<b>Extra Ordinary Items (Net of Tax)</b>	-249.98	-	-	-249.98	-	-
XIII	<b>Net Profit for the period (XI-XII)</b>	<b>381.95</b>	<b>160.32</b>	<b>134.88</b>	<b>3,849.98</b>	<b>3,357.45</b>	<b>3,501.14</b>
XIV	<b>Other Comprehensive Income</b>						
	1. (a) Items that will not be reclassified to Profit or Loss	-0.56	-0.54	-	-1.50	-	-2.06
	(b) Income tax relating to items that will not be reclassified to Profit or Loss	-	-	-	-	-	-
	2. (a) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	(b) Income tax relating to items that will be reclassified to Profit or Loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>-0.56</b>	<b>-0.54</b>	<b>-</b>	<b>-1.50</b>	<b>-</b>	<b>-2.06</b>
XV	<b>Total Comprehensive Income for the period (VII + VIII)</b>	<b>382.51</b>	<b>160.86</b>	<b>134.88</b>	<b>3,851.48</b>	<b>3,357.45</b>	<b>3,503.20</b>
XVI	<b>Share in Profit / (Loss) of minority share holder</b>	-1.38	-1.09	-	-4.69	-	-1.53
XVII	<b>Profit related to Holding Company</b>	<b>383.89</b>	<b>161.95</b>	<b>134.88</b>	<b>3,856.18</b>	<b>3,357.45</b>	<b>3,504.73</b>
XVI	<b>Paid Up Equity Share Capital (Face Value Rs. 10/- each)</b>	1,900.40	1,900.40	1,900.40	1,900.40	1,900.40	1,900.40
XVII	<b>Reserve &amp; Surplus</b>	58,893.03	58,508.20	55,653.99	58,893.03	55,653.99	55,416.93
XVI	<b>Earning per share (of Rs 10/- each) (not annualised) Basic &amp; Diluted</b>	2.02	0.85	0.71	20.29	17.67	18.44

### NOTES:


- (1) The consolidated financial results were reviewed by the Audit Committee in meeting held on 15 January 2024 and were thereafter approved by the Board of Directors at its meeting held on 18 January 2024.
- (2) The company is dealing in one major product segment, i.e. Seed Cultivation.
- (3) The results have been consolidated with Nath Bio-Genes CA, Uzbekistan, wherein the company is holding 90% of equity (Operational since March 2023)
- (4) Investor complaints - Opening Balance - 0, Received and Resolved - 0, Closing Balance - 0
- (5) The figures have been regrouped/rearranged where ever necessary.

Place : Aurangabad

Date : 18 January 2024

FOR NATH BIO-GENES (INDIA) LTD

SATISH KAGLIWAL  
MANAGING DIRECTOR  
DIN 00119601





**INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED CONSOLIDATED IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.**

To,  
The Board of Directors,  
Nath Bio-Genes India Limited  
Aurangabad.

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of Nath Bio-Genes (India) Limited ("the Parent") and its Subsidiary (the Parent and its Subsidiary together referred to as "the Group"), and its share of the net profit after tax for the quarter ended on 31st December, 2023 and year to date results for the period 1st April, 2023 to 31st December, 2023 ("The Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31st December, 2022 and the corresponding period from 1st October, 2022 to 31st December, 2022 as reported in these financial results have been approved by the Parent's Board of Directors and have been reviewed by us.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.  
  
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
4. The Statement includes the result of the subsidiary, Nath Bio-Genes CA, Uzbekistan for the current quarter but does not include for the corresponding quarter as the same was non-existent.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The interim financial results of the Nath Bio-Genes CA, Uzbekistan, subsidiary included in the consolidated unaudited financial results, reflects total assets of Rs.21.02 lakhs as at 31st December, 2023 and total revenue of Rs. Nil for the quarter ended 31<sup>st</sup> December,2023 and for the period from 1st April, 2023 to 31st December, 2023. The subsidiary has incurred total Net Loss after tax of Rs. 13.78 Lakhs and Rs, 48.46 Lakhs, for the quarter ended 31st December, 2023 and for the period from 1<sup>st</sup> April, 2023 to 31<sup>st</sup> December, 2023 respectively, whose interim financial results have not been reviewed by us.

Our Conclusion is not modified in respect of this matter.

**For Gautam N Associates**  
**Chartered Accountants**  
**FRN: 103117W**

*Gautam*



**Gautam Nandawat**  
**Partner**  
**M No. 032742**  
**UDIN: 24032742BKCRNO4340**

**Place: Chatrapati Sambhajnagar**  
**Date: 18<sup>th</sup> January 2024**